Liquid Biopsy Core

液体活检核心

基本信息

批准号：
10620229
负责人：
Amir Goldkorn
金额：
$ 21.62万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1996
资助国家：
美国
起止时间：
1996-12-01 至 2026-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10620229
关键词：
Academia Address American Association of Cancer Research American Society of Clinical Oncology Atlases Award Biological Assay Biological Markers Blood Blood specimen Budgets California Cancer Center Support Grant Cancer Detection Cell Count Cell Separation Cells Charge Clinical Clinical Sciences Collaborations Communities Comprehensive Cancer Center Core Biopsy DNA Library DNA amplification DNA methylation profiling Development Direct Costs Disease Management Emerging Technologies Expression Profiling Extramural Activities Extramural Funding Mechanisms Faculty Foundations Funding Gene Dosage Generations Genomics Goals Grant High-Throughput Nucleotide Sequencing Hour Immune checkpoint inhibitor Immunofluorescence Immunologic Industry Institution Institutional Review Boards International Last Name Malignant Neoplasms Malignant neoplasm of urinary bladder Methodology Methods Methylation Microfluidics Microscopy Mission Molecular Mutation Names Neoplasm Circulating Cells Nucleic Acids Occupational activity of managing finances Oral Paper Patients Peer Review Phase Phenotype Plasma Plasma Cells Primary carcinoma of the liver cells Process Prognosis Prostate Cancer therapy Protocols documentation Publishing RNA RNA amplification Recovery Regulation Research Research Personnel Resource Sharing Role Seminal Services Slide Southwest Oncology Group Strategic Planning System TACSTD1 gene Technology Time Translational Research Universities University of Southern California Norris Cancer Center Update X-Ray Computed Tomography anticancer research cell free DNA commercialization cost effective empowerment epigenomics hormone therapy improved industry partner insight instrument liquid biopsy malignant breast neoplasm member men multiple omics new technology new therapeutic target novel operation precision medicine predictive signature prognostic programs prospective radiomics research and development response sample collection therapeutic biomarker timeline transcriptome sequencing transcriptomic profiling translational research program tumor tumor DNA tumor microenvironment user-friendly whole genome

项目摘要

PROJECT SUMMARY – Liquid Biopsy Shared Resource The mission of the USC Norris Comprehensive Cancer Center (NCCC) Liquid Biopsy Shared Resource (LBC) is to provide a state-of-the-art multi-platform facility for capture and analysis of circulating tumor cells (CTCs) and matched plasma nucleic acids for cancer research. NCCC Administration oversees LBC with Amir Goldkorn MD continuing in his role as the faculty Director and founder in 2015. Goldkorn provides the strategic direction for LBC, overseeing technology, operations, and financial management. LBC is located in NCCC wet lab research space. During the current grant cycle, noteworthy enhancements include: 1) expanded CTC enrichment platforms from 5 to 12; 2) added new microfluidic cell separation systems, an automated slide stainer and RareCyte high-content CTC analysis and recovery system; 3) developed new workflows to combine recovery of single CTCs for whole genome amplification and gene copy number analysis, rapid enrichment of live CTCs for RNAseq, chip array profiling of plasma cfDNA methylation, and CTC immunofluorescence assays; 4) added parallel cell-free DNA banking and non-EpCAM-dependent CTC enrichment for EpCAM-poor tumors; and 5) developed cost-effective workflows. In the next grant cycle, LBC will be expanding research partnerships with R&D teams at various industry partners to co-develop exciting new liquid biopsy biomarker assays with strong potential for commercialization. During the current grant period from 2015-2020, LBC served 23 full NCCC members in 3 research programs – Translational and Clinical Sciences (TACS), Tumor Microenvironment (TME), and Genomic and Epigenomic Regulation (GER), resulting in 20 intramural and extramural funding applications, 15 of which were funded for $6.75M in direct costs. Since 2015, LBC has contributed to 5 published papers and 11 abstracts and processed 5,396 blood samples. The anticipated annual budget of LBC in the first year of the next grant cycle is $400,712, yet the CCSG request is $134,712. Accordingly, LBC leverages extensive institutional and recharge support and seeks only 34% from CCSG funds.

项目摘要 – 液体活检共享资源南加州大学诺里斯综合癌症中心 (NCCC) 液体活检共享资源 (LBC) 的使命旨在提供最先进的多平台设施来捕获和分析循环肿瘤细胞（CTC） NCCC 管理局与 Amir Goldkorn 一起监督 LBC。 MD 于 2015 年继续担任教务主任和创始人。Goldkorn 提供了战略方向 LBC 负责技术、运营和财务管理。LBC 位于 NCCC 湿实验室。在当前的资助周期中，值得注意的改进包括：1）扩大了 CTC 的丰富范围。平台从 5 个增加到 12 个；2) 添加了新的微流体细胞分离系统、自动玻片染色机和 RareCyte高内涵CTC分析和回收系统；3）开发了新的工作流程以结合回收用于全基因组扩增和基因拷贝数分析的单个 CTC，快速富集活 CTC 添加了 RNAseq、血浆 cfDNA 甲基化芯片阵列分析和 CTC 免疫荧光测定；针对 EpCAM 缺乏的肿瘤进行平行无细胞 DNA 库和非 EpCAM 依赖性 CTC 富集；以及 5) 开发了具有成本效益的工作流程，在下一个资助周期中，LBC 将扩大与以下机构的研究合作伙伴关系。各个行业合作伙伴的研发团队共同开发令人兴奋的新型液体活检生物标志物检测方法，具有强大的在 2015 年至 2020 年的当前资助期内，LBC 为 23 个完整的 NCCC 提供服务。 3 个研究项目的成员 – 转化与临床科学 (TACS)、肿瘤微环境 (TME)、和基因组和表观基因组调控 (GER)，产生了 20 份校内和校外资助申请，其中 15 项获得了 675 万美元的直接费用资助，自 2015 年以来，LBC 已发表了 5 篇论文。 11 份摘要并处理了 5,396 个血液样本 LBC 第一年的预期年度预算。下一个拨款周期为 400,712 美元，而 CCSG 的请求为 134,712 美元，因此，LBC 充分利用了杠杆。机构和充值支持，仅寻求 CCSG 资金的 34%。